ECSP056105A - ALFA CARBOXYLIC ACIDS REPLACED AS PPAR MODULATORS - Google Patents

ALFA CARBOXYLIC ACIDS REPLACED AS PPAR MODULATORS

Info

Publication number
ECSP056105A
ECSP056105A EC2005006105A ECSP056105A ECSP056105A EC SP056105 A ECSP056105 A EC SP056105A EC 2005006105 A EC2005006105 A EC 2005006105A EC SP056105 A ECSP056105 A EC SP056105A EC SP056105 A ECSP056105 A EC SP056105A
Authority
EC
Ecuador
Prior art keywords
carboxylic acids
alfa
ppar modulators
acids replaced
ppar
Prior art date
Application number
EC2005006105A
Other languages
Spanish (es)
Inventor
Simon Bailey
Paul Stuart Humphries
Donald James Skalitzky
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP056105A publication Critical patent/ECSP056105A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ácidos carboxílicos alfasustituidos de fórmula (I): en la que R1 y R2 son como se han definido en la memoria descriptiva y R3 es en las que Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, anillo A, y p son como se han definido en la memoria descriptiva; las composiciones farmacéuticas conteniendo cantidades eficaces de dichos compuestos o sus sales son útiles para tratar PPAR, específicamente trastornos relacionados con PPAR a/?, tales como diabetes, dislipidemia, obesidad y trastornos inflamatorios.Alpha-substituted carboxylic acids of formula (I): in which R1 and R2 are as defined in the specification and R3 is where Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, ring A, and p are as defined in the specification; Pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically disorders related to PPAR a / ?, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

EC2005006105A 2003-04-15 2005-10-14 ALFA CARBOXYLIC ACIDS REPLACED AS PPAR MODULATORS ECSP056105A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46321303P 2003-04-15 2003-04-15

Publications (1)

Publication Number Publication Date
ECSP056105A true ECSP056105A (en) 2006-03-01

Family

ID=33300053

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006105A ECSP056105A (en) 2003-04-15 2005-10-14 ALFA CARBOXYLIC ACIDS REPLACED AS PPAR MODULATORS

Country Status (25)

Country Link
EP (1) EP1615899A1 (en)
JP (1) JP2006523671A (en)
KR (1) KR20060009846A (en)
CN (1) CN1805943A (en)
AP (1) AP2005003418A0 (en)
AR (1) AR044514A1 (en)
AU (1) AU2004230316A1 (en)
BR (1) BRPI0409429A (en)
CA (1) CA2521915A1 (en)
CL (1) CL2004000800A1 (en)
EA (1) EA200501462A1 (en)
EC (1) ECSP056105A (en)
IS (1) IS8033A (en)
MA (1) MA27764A1 (en)
MX (1) MXPA05010967A (en)
NL (1) NL1025946C2 (en)
NO (1) NO20055370L (en)
OA (1) OA13157A (en)
PA (1) PA8600201A1 (en)
PE (1) PE20050415A1 (en)
TN (1) TNSN05262A1 (en)
TW (1) TW200510353A (en)
UY (1) UY28266A1 (en)
WO (1) WO2004092145A1 (en)
ZA (1) ZA200508362B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
KR20080019213A (en) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 Thiazole compound and its use method
BRPI0622100A2 (en) 2006-10-30 2011-12-27 Chroma Therapeutics Ltd hydroxamates as histone deacetylase inhibitors
US20110021534A1 (en) * 2007-03-08 2011-01-27 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
MX2009012613A (en) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Heteroaryl substituted thiazoles and their use as antiviral agents.
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
CA2728228A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
MX2011001090A (en) 2008-07-28 2011-03-15 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds.
ES2463826T3 (en) 2009-06-08 2014-05-29 Gilead Sciences, Inc. HDAC inhibitor compounds of cycloalkylcarbamate benzamide aniline
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
DE102010055499A1 (en) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
FR2982858B1 (en) * 2011-11-18 2013-11-29 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
FR2984322B1 (en) * 2011-12-16 2013-12-20 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
RU2015143906A (en) 2013-03-14 2017-04-18 Дженентек, Инк. SUBSTITUTED TRIAZOLOPYRIDINES AND WAYS OF THEIR APPLICATION
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (en) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド Therapeutic compounds and methods of use thereof
BR112017024853A2 (en) 2015-05-22 2018-08-07 Genentech Inc compound, pharmaceutical composition, method for treating a disease or condition in a mammal, for treating itching in a mammal, for treating or prophylaxis and use of a compound
MA42683A (en) 2015-08-27 2018-07-04 Genentech Inc THERAPEUTIC COMPOUNDS AND THEIR METHODS OF USE
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
JP2018535234A (en) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド Substituted benzamides useful as sodium channel blockers
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
CN110546148A (en) 2017-03-24 2019-12-06 基因泰克公司 4-piperidine-N- (pyrimidin-4-yl) chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (en) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 Substituted hydrogen-pyrido-azines as sodium channel inhibitors
TW202003490A (en) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1088824E (en) * 1999-09-30 2004-04-30 Pfizer Prod Inc BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS
BR0207227A (en) * 2001-02-15 2004-02-10 Pfizer Prod Inc Ppar proliferating activated receptor compounds

Also Published As

Publication number Publication date
AP2005003418A0 (en) 2005-12-31
PA8600201A1 (en) 2005-02-04
JP2006523671A (en) 2006-10-19
WO2004092145A8 (en) 2005-05-12
IS8033A (en) 2005-09-15
EA200501462A1 (en) 2006-04-28
AR044514A1 (en) 2005-09-14
UY28266A1 (en) 2004-11-30
BRPI0409429A (en) 2006-04-18
NL1025946A1 (en) 2004-10-18
TW200510353A (en) 2005-03-16
OA13157A (en) 2006-12-13
CA2521915A1 (en) 2004-10-28
MXPA05010967A (en) 2005-11-28
CL2004000800A1 (en) 2005-03-04
CN1805943A (en) 2006-07-19
PE20050415A1 (en) 2005-06-13
WO2004092145A1 (en) 2004-10-28
TNSN05262A1 (en) 2007-07-10
ZA200508362B (en) 2006-11-29
MA27764A1 (en) 2006-02-01
EP1615899A1 (en) 2006-01-18
NL1025946C2 (en) 2005-02-01
KR20060009846A (en) 2006-02-01
NO20055370L (en) 2006-01-12
NO20055370D0 (en) 2005-11-14
AU2004230316A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
ECSP056105A (en) ALFA CARBOXYLIC ACIDS REPLACED AS PPAR MODULATORS
PE20130311A1 (en) COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING TRACK
AR087995A1 (en) DERIVATIVES OF N- (4 - {[6,7-BIS (METILOXI) QUINOLIN-4-IL] OXI} PHENYL) -N- (4-FLUOROPHENYL) CICLOPROPAN-1,1-DICARBOXAMIDA
UY30498A1 (en) NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CY1118973T1 (en) DERIVATIVES OF AMOID Benzoimidazole-carboxylic acid for the treatment of metabolic or cardiovascular diseases
EA201070422A1 (en) OXADIAZOL DERIVATIVES
CO7141456A2 (en) Aril-sultamo derivatives as rorc modulators
EA200701176A1 (en) NEW NAPHTHALINE COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
ATE432272T1 (en) AMINOPHENYL DERIVATIVES AS NEW INHIBITORS OF HISTONE DEACETYLASE
EA201001682A1 (en) Derivatives of phenyl and benzodioxynyl-substituted indazols
EA201500953A1 (en) 3-ACETYLAMINO-1- (PENILHETEROARYLAMINOCARBONYL OR PHENILGETEROARILCARBONYLAMINO) BENZENE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISABILITIES
UY31046A1 (en) SUBSTITUTED DERIVATIVES OF N- (3,4-DIHIDRO-2H-CROMEN-3-IL) FORMAMIDA AND N- (1, 2,3, 4-TETRAHIDRONAFTALEN-2-IL) FORMAMIDA, SALTS OF THE SAME, COMPOSITIONS THAT CONTAIN THEM , PROCEDURES FOR PREPARATION AND APPLICATIONS
AR078278A1 (en) ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.
PT1716152E (en) HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC RECEPTOR FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
AR058807A1 (en) 5- (PHENYLYSOXAZOLETOXI) -TRIAZOL-3-IL PIRIDINES REPLACED, FOR THE TREATMENT OF DISORDERS MEDIATED BY THE RECEIVER MGLUR5
SV2004001555A (en) DIFENILAZETIDINONES CATIONICAMENTE REPLACED, PROCESSES FOR THEIR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USES
SV2004001549A (en) DIFENILAZETIDINONES REPLACED IN RING, PROCEDURE FOR PREPARATION, MEDICINES THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE
EA201300436A8 (en) JOINT CRYSTALS AND SALTS OF CCR3 INHIBITORS
CY1114354T1 (en) NEW BENZAMIDI PRODUCERS AS BRADYKININ COMPONENTS
SE0403171D0 (en) New compounds
AR070813A1 (en) NEW DERIVATIVES OF 1- BENCIL -3-HYDROXIMETHYLINDAZOL AND ITS USE IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1 AND CX3CR1
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
EA201892264A1 (en) Derivatives of tetrahydroisoquinoline
SE0300091D0 (en) Novel compounds